IMI_SOPHIA

Congrats to Francois Pattou and team for their research identifying two distinct subtypes of MASLD (metabolic dysfunction-associated steatotic liver disease) – liver-specific and cardiometabolic – each with distinct risk profiles 📢  find out more in Nature Portfolio's Nature Medicine

Congratulations to SOPHIA PhD researcher Lucas Schreurs 🌠 who won an award for Best New Investigator Poster Research Presentation at the 2024 ISPOR—The Professional Society for Health Economics and Outcomes Research meeting in Barcelona 🏆 See "A Mixed-Methods Blueprint for Obesity Healthcare Policy: From Research to Action" here: https://lnkd.in/eS8NmJEv This work comes at the final stages of our 5-year IMI_SOPHIA research project, where look at Obesity Healthcare Policy and use mixed-methods to move from research to real-world action 💪 stay tuned for our SOPHIA Blueprint for Change report, coming soon! Third-i bvba ____________________________ SOPHIA has received funding from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No. 875534. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA - European Federation of Pharmaceutical Industries and Associations, Breakthrough T1D and Obesity Action Coalition through the Innovative Health Initiative (IHI).

Congrats to Lucas Schreurs and our SOPHIA partners for their work at ISPOR—The Professional Society for Health Economics and Outcomes Research - and for being awarded a top 5% poster award! 🏆

Will you be at the ISPOR—The Professional Society for Health Economics and Outcomes Research European meeting in Barcelona? Come see our IMI_SOPHIA mixed-methods blueprint for obesity healthcare policy! #ISPOReurope

It was a great pleasure to contribute to this highly relevant work under the umbrella of IMI_SOPHIA , demonstrating once again the vital role of close collaboration between academia, the pharmaceutical industry and other stakeholders in producing top-notch research. A heartfelt thank you goes to our bright and dedicated colleagues, Daniel Coral and Femke Smit, for driving this work and kudos to all the authors! I extend my gratitude to Boehringer Ingelheim's long-term collaborator Philipp Wild from University Medical Center Mainz and the young talented Alex Gieswinkel for their contributions and for incorporating the Gutenberg Health Study into this remarkable narrative. Enjoy our publication in Nature Medicine where a novel prediction algorithm is introduced that identifies five unique phenotypic profiles characterized by an atypical relationship between BMI and common risk biomarkers. Stay tuned for more to come! https://lnkd.in/eHedFpCW

Phenotyping of #obesity has always been challenging and lacking behind other chronic diseases such as cancer, diabetes or CVD. Here, in this paper, the IMI_SOPHIA team and collaborators succeed in subclassifying different profiles of obesity based on mostly simply and largely available variables or biomarkers. They validated their findings in multiple cohorts. Then the found different associations between the phenotypes and a range of obesity related complications. They also found differences in the relationships between the phenotypes and the risk of incident T2 #diabetes and CVD. This is a great step forward in improving our understanding of "obesities" and help moves the field to a personalised approach. Whether the phenotypes have different pathogenesis and predict treatment responses remain to be seen. Congratulations to the team. https://lnkd.in/d_EC5_h5

Some papers make me so proud, and this is one! In our latest publication in Nature Medicine, we described a powerful precision prediction algorithm that leverages heterogeneity in obesity for the prediction of cardiovascular (and other) diseases. This work was led by one of my amazing, recently graduated, doctoral students Daniel Coral MD PhD as part of the IMI_SOPHIA consortium. It's the second paper from Daniel's PhD these (the first published in Nature Metabolism last year). Both papers use "discordancy" algorithms that expose phenotypic divergencies from the population average, highlighting subgroups of people with obesity whose disease risk profile and treatment requirements defy common expectations. We used the information derived from these analyses to build new precision medicine prediction models that enhance conventional approaches. Congratulations to the other joint first authors Dr. Femke Smit (Maastricht University) and Dr. Ali Faraneh (Erasmus University Rotterdam). https://rdcu.be/dXXoI #precisionmedicine #obesity Lund University Diabetes Centre LUDC Lund University Innovative Health Initiative (IHI) Nature Portfolio

It's here! Our major SOPHIA findings have been published in Nature Medicine 📣 🩺 Did you know that there are distinct sub-types of obesity? Using a pioneering clinical risk prediction algorithm, SOPHIA researchers have separated obesity into 5 separate diagnostic profiles - each with differing health consequences and treatment implications. Read more here: https://lnkd.in/eXprs2ZZ Congratulations to Daniel Coral, Femke Smit, Ali Farzaneh, Alex Gieswinkel, Juan Fernandez Tajes, Thomas Sparsø, Carl Delfin, Pierre Bauvin, Kan Wang, Marinella Temprosa, Diederik De Cock, Jordi Blanch, José Manuel Fernández-Real, Rafael Ramos, M. Kamran Ikram, Maria Gomez, Maryam Kavousi, Marina Panova-Noeva, MD, MSc, PhD, Philipp Wild, Carla van der Kallen, Michiel Adriaens, Marleen van Greevenbroek, Ilja Arts, Carel Le Roux, Fariba Ahmadizar, Tim Frayling, Giuseppe 'Nick' Giordano, Ewan Pearson, Paul Franks PhD MPhil MS FTOS and the entire SOPHIA consortium! ____________________________ SOPHIA has received funding from the Innovative Medicines Initiatives in 2 Joint Undertaking under grant agreement No. 875534. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA - European Federation of Pharmaceutical Industries and Associations, Breakthrough T1D and Obesity Action Coalition through the Innovative Health Initiative (IHI).

Did you know that obesity is also prevalent among those with type 1 diabetes? 📣 Our latest IMI_SOPHIA publication assesses the prevalence of overweight and obesity in those with and without type 1 diabetes in Belgium, Kuwait and Mexico. Find out more about the need for targeted healthcare strategies that address obesity and T1D together. https://lnkd.in/daQpCe-h Thanks to Ebaa Al Ozairi, Nele Steenackers, Sofía Pazmiño, Abdulnami Allatar, Jumana Al Kandari, Paloma Almeda-Valdez, Neftali Eduardo Antonio-Villa, Carl Delfin, Raquel Faradji, Aili Garcia Tuomola, Mohammad Irshad, Joseph Craig Longenecker, MD, MPH, PhD, Jonathan Rosen, Carmen Hurtado, Thomas Sparsø, astrid lavens, chantal mathieu, Bart Van der Schueren and Carel Le Roux for their fantastic work 👏 ____________________________ SOPHIA has received funding from the Innovative Medicines Initiatives in 2 Joint Undertaking under grant agreement No. 875534. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA - European Federation of Pharmaceutical Industries and Associations, Breakthrough T1D, JDRF International and Obesity Action Coalition through the Innovative Health Initiative (IHI).

Dear Network, A lot of people are routinely astounded by the amount and complexity of paradigm shifts which can be traced back to my door down the years. My simple response is that "It takes a village". Some things need to be achieved through partnerships driven by my cause-driven SME under its own brand as opposed to when I was representing the policy interests of the 20000+ European Association for the Study of Obesity (EASO) health professionals, researchers and public health professionals across 36 WHO EURO Region countries at EASO for 5 1/2 years as Head of Policy. Below is why I keep on having to explain that I can't work full time for another organisation until the end of the heavy lifting of this project at the end of 2024. The IMI_SOPHIA (On Obesity Phenotypes - what does it take to get the right treatment, to the right person at the right time?) is one such case in point. The Work Package I've been co-leading from the non-industry side of the partnership since 2020 has always stood out as the "maverick" Work Package. Why? Because we haven't been a conventional cohort "number crunching" piece of work. We've been the value-based healthcare, #ManagementTheory group that has been tasked with making sense of the research from the investigative Work Packages and working out Real World solutions based on the concept of Shared Value. We have had some hard and robust discussions all the way through because we have been working from a blank sheet. We have proactively listened and, I hope, heard a number of different stakeholders as to their needs and challenges in shifting the narrative on #Obesity. We are now at the point of pulling it all together in our Blueprint for Change. Our "half-way house outing" towards finalisation of our Blueprint for change will be at ISPOR Europe. We are excited to have our abstract recognised within the top 5% of abstract finalists at the upcoming ISPOR—The Professional Society for Health Economics and Outcomes Research Europe Congress on 17 - 20 November 2024 in Barcelona! Although the abstract has been accepted, the work does not stop there! We will keep you posted on the final toolkit "Blueprint for change". We are working on a practical tool which has been loudly requested on the "how" to get all of this done. #WatchThisSpace 👇 👇 👇